This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul Palmberg, MD, PhD

Arch Ophthalmol. 1995;113(8):985-986.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS issue of the ARCHIVES, Strahlman and associates¹ report a 1-year study of the safety profile and efficacy of a topical carbonic anhydrase inhibitor (CAI), dorzolamide hydrochloride (Trusopt), as either primary or supplemental therapy for primary open-angle glaucoma and ocular hypertension. This is the first topical CAI to show sufficient efficacy for clinical use and that appears to nearly match the pressure-lowering of oral CAIs without having their systemic side effects. Having advanced to Food and Drug Administration phase 3 trials, it was approved early this year² and marketed in June.

The quest to develop a topically active CAI has taken a long time, generating apt comparisons to the biblical 40-year journey in the wilderness needed to reach the promised land. This journey also was circuitous and skeptics wondered if it would be completed.

The rationale for the development of a topically active CAI was to eliminate . . . [Full Text PDF of this Article]

Author Affiliations
Miami, Fla

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?